-2%
Sofosbuvir + Velpatasvir
This fixed-dose antiviral combination is prescribed for adults and children aged 3 years and above diagnosed with chronic Hepatitis C Virus (HCV) infection, regardless of genotype (1 through 6), in the following patient populations:
- Without cirrhosis or with compensated cirrhosis (Child-Pugh A)
- With decompensated cirrhosis (Child-Pugh B or C) in combination with ribavirin
Hepatitis B reactivation can occur during or after therapy. Test all patients for HBV markers prior to treatment. Monitor and manage HBV-positive patients carefully.
Use with caution; hospitalization and close ECG monitoring may be needed.
All ribavirin-related warnings apply when used with Sofosbuvir/Velpatasvir.
Sofosbuvir: A nucleotide analog prodrug that targets NS5B RNA-dependent RNA polymerase, critical for viral RNA replication. It’s converted intracellularly to GS-461203 (triphosphate form), which halts viral replication by acting as a chain terminator.
Velpatasvir: A direct-acting antiviral agent that inhibits the NS5A protein, which is essential for HCV RNA replication and virion assembly.
This dual action targets different stages of the viral life cycle, making the combination broadly effective across HCV genotypes.
Cardiac Safety: Neither Sofosbuvir (up to 3x the recommended dose) nor Velpatasvir (up to 5x the recommended dose) significantly prolong the QT interval, based on thorough QT studies.